

Global Bi-Specific Antibodies Market Forecast to 2022

<https://marketpublishers.com/r/G8796F32799EN.html>

Date: August 2018

Pages: 80

Price: US\$ 2,500.00 (Single User License)

ID: G8796F32799EN

Abstracts

Bi-specific antibody is one of the most potentially powerful tools which have emerged in the biopharmaceutical industry. The bi-specific antibodies intend to provide the next generation of targeted biologics by engaging two different targets simultaneously. These drugs offer several advantages over traditional treatment options for various diseases such as cancer. They have fewer side effects due to high specificity towards disease target. These antibodies are of particular importance for patients who experience recurrence or resistance to drugs.

According to the RNCOS report entitled “Global Bi-Specific Antibodies Market Forecast to 2022”, the Global Bi-Specific Antibodies Market is anticipated to witness a double digit growth during the forecast period. The report provides information about the current and future scenario of this market. The report also highlights the major drivers, such as increasing incidences of diseases and increasing demand for effective treatment, for the Global Bi-Specific Antibodies Market. Furthermore, the report also gives information related to the commercially available bi-specific antibody drugs.

Moreover, few hindrances, such as production hurdles and regulatory challenges, which are slowing down the growth of the Global Bi-Specific Antibodies Market, have also been mentioned in the report. In addition, the report also highlights various trends and developments taking place in this market.

Furthermore, in this report, we have structured the information regarding bi-specific antibodies at various stages of clinical development. The pipeline chapter provides in depth analysis of bi-specific antibodies by clinical phase, indications for which they are being developed, and technology. Additionally, the study provides all-inclusive current analysis of various bi-specific antibodies in advanced as well as early stages of development. Moreover, our report places emphasis on the strategic collaborations that can impact industry’s growth.

The prominent players in Global Bi-Specific Antibodies Market have been discussed in the last section of the report. A brief business overview and financial information about each of these players has been provided, along with their product portfolios, product pipeline and recent developments. Overall, the research contains exhaustive information that will help clients in formulating market strategies and assessing opportunity areas in the Global Bi-Specific Antibodies Market.

Contents

1. ANALYST VIEW

2. RESEARCH METHODOLOGY

3. BI-SPECIFIC ANTIBODIES – AN INTRODUCTION

4. GLOBAL BI-SPECIFIC ANTIBODIES MARKET OUTLOOK TO 2022

4.1 BLINCYTO

4.2 Hemlibra

4.3 Removab

5. BI-SPECIFIC ANTIBODIES PIPELINE ANALYSIS

5.1 By Clinical Phase

5.2 By Indication

5.3 By Technology

6. MARKET DYNAMICS

6.1 Drivers

6.1.1 Rising Global Cancer Epidemics

6.1.2 Bi-Specific Antibodies Improving the Targeting Capabilities of Traditional mAbs

6.1.3 T-cells in Bi-Specific Antibodies Mediated Immunotherapy

6.1.4 Increasing Demand for Bi-Specific/Double Barreled Antibodies

6.2 Challenges

6.2.1 Production Hurdles in Bi-Specific Antibodies Development

6.2.2 Regulatory Challenges

7. CURRENT STATUS OF MAJOR BI-SPECIFIC ANTIBODIES IN PIPELINE

7.1 BLINCYTO/Blinatumomab – Amgen Inc.

7.2 ABT-122 – AbbVie Inc.

7.3 MCLA-128 – Merus N.V.

7.4 ALX-0761/M1095 - Ablynx

7.5 MGD006/S80880 – MacroGenics, Inc.

7.6 ZW25 – Zymeworks Inc.

8. TRENDS AND DEVELOPMENTS

- 8.1 Bi-specific Antibody Application for Tumor Therapy
- 8.2 Bi-specific Antibodies Development Against Myeloma
- 8.3 Bi-specific Antibody Agreement with EpimAb Biotherapeutics
- 8.4 B-specific Antibody Development against Multiple Ebola viruses

9. STRATEGIC COLLABORATIONS IN THE BI-SPECIFIC ANTIBODIES INDUSTRY

10. COMPETITIVE ASSESSMENT

- 10.1 Amgen Inc.
- 10.2 F. Hoffman La Roche Ltd.
- 10.3 AbbVie Inc.
- 10.4 OncoMed Pharmaceuticals, Inc.
- 10.5 Glenmark Pharmaceuticals Limited
- 10.6 Xencor, Inc.
- 10.7 MacroGenics, Inc.
- 10.8 Aptevo Therapeutics Inc.
- 10.9 Ligand Pharmaceuticals, Inc.
- 10.10 Regeneron Pharmaceuticals, Inc.
- 10.11 Fresenius SE & Co. KGaA
- 10.12 Merus N.V.

List Of Figures

LIST OF FIGURES:

Figure 3-1: Bi-Specific Antibodies - Mechanism of Action

Figure 4-1: Global - Bi-Specific Antibodies Market (Million US\$), 2016-2022

Figure 4-2: Global - BLINCYTO Sales (Million US\$), 2016 & 2017

Figure 5-1: Global - Bi-Specific Antibodies Pipeline by Clinical Phase (%), 2017

Figure 5-2: Global - Bi-Specific Antibodies Pipeline by Indication (%), 2017

Figure 5-3: Global - Bi-Specific Antibodies Pipeline by Technology (%), 2017

Figure 6-1: Global - Cancer & Other Non-Communicable Disease Epidemics (%), 2016

Figure 10-1: Amgen Inc. - Breakup of Revenue by Geography (%), 2016

Figure 10-2: F. Hoffman La Roche Ltd. - Breakup of Group Sales by Business Segments (%), 2016

Figure 10-3: F. Hoffman La Roche Ltd. - Breakup of Group Sales by Geography (%), 2016

Figure 10-4: AbbVie Inc. - Breakup of Net Revenues by Geography (%), 2016

Figure 10-5: Glenmark Pharmaceuticals Limited - Breakup of Revenue by Geography (%), FY2017

Figure 10-6: Xencor, Incl. - Breakup of Revenue by Product Programs (%), 2016

Figure 10-7: Ligand Pharmaceuticals, Inc. - Breakup of Revenue by Operations (%), 2016

Figure 10-8: Ligand Pharmaceuticals, Inc. - Breakup of Royalty Revenue by Program (%), 2016

Figure 10-9: Ligand Pharmaceuticals, Inc. - Breakup of Material Sales by Use (%), 2016

Figure 10-10: Fresenius SE & Co. KGaA - Breakup of Sales by Business Segments (%), 2016

Figure 10-11: Fresenius SE & Co. KGaA - Breakup of Sales by Geography (%), 2016

List Of Tables

LIST OF TABLES:

- Table 4-1: Global - Potential Patients for BLINCYTO (2017)
- Table 4-2: Global - Potential Patients for BLINCYTO (2020)
- Table 4-3: Global - Major Ongoing Trials for BLINCYTO
- Table 5-1: Global - Major Bi-Specific Antibodies in Pipeline
- Table 9-1: Global - Major Strategic Collaborations in the Bi-Specific Antibodies Industry
- Table 10-1: Top Companies by Bi-Specific Antibodies in Pipeline
- Table 10-2: Amgen Inc. - Product Portfolio
- Table 10-3: Amgen Inc. - Major Bi-Specific Antibodies in Pipeline
- Table 10-4: Amgen Inc. - Key Financials (Million US\$), 2014-2016
- Table 10-5: F. Hoffman La Roche Ltd. - Major Bi-Specific Antibodies in Pipeline
- Table 10-6: F. Hoffman La Roche Ltd. - Key Financials (Million US\$), 2014-2016
- Table 10-7: AbbVie Inc. - Major Bi-Specific Antibodies in Pipeline
- Table 10-8: AbbVie Inc. - Key Financials (Million US\$), 2014-2016
- Table 10-9: OncoMed Pharmaceuticals, Inc. - Major Bi-Specific Antibodies in Pipeline
- Table 10-10: OncoMed Pharmaceuticals, Inc. - Key Financials (Million US\$), 2014-2016
- Table 10-11: Glenmark Pharmaceuticals Limited - Major Bi-Specific Antibodies in Pipeline
- Table 10-12: Glenmark Pharmaceuticals Limited - Key Financials (Million US\$), FY2015-FY2017
- Table 10-13: Xencor, Inc. - Major Bi-Specific Antibodies in Pipeline
- Table 10-14: Xencor, Inc. - Key Financials (Million US\$), 2014-2016
- Table 10-15: MacroGenics, Inc. - Major Bi-Specific Antibodies in Pipeline
- Table 10-16: MacroGenics, Inc. - Key Financials (Million US\$), 2014-2016
- Table 10-17: Aptevo Therapeutics - Major Bi-Specific Antibodies in Pipeline
- Table 10-18: Aptevo Therapeutics Inc. - Key Financials (Million US\$), 2015-2016
- Table 10-19: Ligand Pharmaceuticals, Inc. - Major Bi-Specific Antibodies in Pipeline
- Table 10-20: Ligand Pharmaceuticals, Inc. - Key Financials (Million US\$), 2014-2016
- Table 10-21: Regeneron Pharmaceuticals, Inc. - Major Bi-Specific Antibodies in Pipeline
- Table 10-22: Regeneron Pharmaceuticals, Inc. - Key Financials (Million US\$), 2015-2017
- Table 10-23: Fresenius SE & Co. KGaA - Product Portfolio
- Table 10-24: Fresenius SE & Co. KGaA - Key Financials (Million US\$), 2014-2016
- Table 10-25: Merus N.V. - Major Bi-Specific Antibodies in Pipeline

I would like to order

Product name: Global Bi-Specific Antibodies Market Forecast to 2022

Product link: <https://marketpublishers.com/r/G8796F32799EN.html>

Price: US\$ 2,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G8796F32799EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970